Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gentronix Awarded Grant of £147,552 by MRC and Technology Strategy Board

Published: Thursday, December 20, 2012
Last Updated: Thursday, December 20, 2012
Bookmark and Share
Company awarded grant from the Biomedical Catalyst programme for an epigenetic based screening assay feasibility study.

Gentronix Ltd., Manchester UK, has been awarded a grant of £147,552 by the Medical Research Council (MRC) and the Technology Strategy Board under the joint £180 million Biomedical Catalyst programme.

The project funded by the award will look at the feasibility of developing a screening assay for compounds that may cause cancer as a result of epigenetic mechanisms.

Before being approved for use, chemicals such as pharmaceuticals, agrochemicals and consumer products have to be tested for genetic toxicity i.e. their potential to change the DNA sequence or the number of chromosomes in a cell.

Exposure to genotoxic chemicals can lead to the development of cancers. They can be identified by routine screening tests used by laboratories such as Gentronix.

There are also non-genotoxic carcinogens that alter patterns of gene expression without changing the number or sequence of chromosomes.

There are currently no widely used screening tests available for these and they might only be identified in later animal exposure studies, which are time consuming, costly and come quite late in product development - an expensive time to fail.

Epigenetics is a relatively new field, concerned with the regulation of genes by chromosome modifications which don’t change the DNA sequence or chromosome numbers.

Epigenetic changes can also lead to the development of cancers and it is this aspect of early toxicology screening that the team at Gentronix Ltd., led by Chief Scientist, Prof. Richard Walmsley will be looking to address under the award.

Gentronix CEO, John Nicholson said “Gentronix has an excellent track record of innovation, and though as a growing company we have to balance innovative research with customer priorities, the award of this grant gives us the opportunity to carry out important fundamental research; the results of which will allow us to make informed decisions about the commercial potential of an epigenetics-based assay as well as making a contribution to the science of genetics”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Announces Strategic Intent to Provide GLP Services
Strategic intention to offer regulatory genotox assays.
Tuesday, March 04, 2014
Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
Gentronix Ltd. has announced the company's first contracted screening project in Japan, with a major Japanese pharmaceutical manufacturer, Kowa Company, Ltd.
Thursday, October 04, 2012
Gentronix Expands Specialist Sales Team in US and Europe
Expansion of sales teams with the appointments of Dorothy Zelent and Simon Johns.
Friday, February 17, 2012
Gentronix Partner with BioQuanta
The agreement covers the commercialization of the Mitoxis® functional metabolomics platform from BioQuanta.
Thursday, November 10, 2011
Gentronix and Apredica Ally to Create Predictive-Toxicology Service
Joint service offering expected to increase drug development success and the safety of new drugs on the market.
Thursday, June 11, 2009
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
New Source of Mutations in Cancer
Recently, a new mutation signature found in cancer cells was suspected to have been created by a family of enzymes found in human cells called the APOBEC3 family.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!